Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 2/20 | 0.33 |
| ▸ | ANPEP | P15144 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6024049 | 0.83 | BRD4 (0.40) | BRD4CYP1A2HIF1ASLC6A2SLC6A4 | |
| SCHEMBL11530722 | 0.81 | BRD4 (0.49) | BRD4CYP1A2HIF1ASLC6A2SLC6A4 | |
| SCHEMBL12363788 | 0.68 | NOTUM (0.44) | BRD4SLC6A2SLC6A4SLC6A3CHRM2 | |
| SCHEMBL3105740 | 0.67 | BRD4 (0.44) | BRD4CYP1A2HIF1ASLC6A2SLC6A4 | |
| SCHEMBL7720880 | 0.67 | CYP1A2 (0.35) | BRD4CYP1A2HIF1A | |
| SCHEMBL16865999 | 0.66 | BRD4 (0.67) | BRD4CYP1A2HIF1A | |
| SCHEMBL13043822 | 0.64 | CYP1A2 (0.44) | BRD4CYP1A2HIF1ASLC6A2SLC6A4 | |
| SCHEMBL2616302 | 0.64 | BRD4 (0.42) | BRD4CYP1A2HIF1ASLC6A2SLC6A4 | |
| SCHEMBL14641237 | 0.64 | BRD4 (0.42) | BRD4CYP1A2HIF1ASLC6A2SLC6A4 | |
| SCHEMBL2784766 | 0.63 | BRD4 (0.44) | BRD4CYP1A2HIF1ACHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7125870-B2 | Isoxazoline derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-10-24 | — | — | US | disclosed |
| US-20040122005-A1 | Isoxazoline derivatives as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme | BRISTOL-MYERS SQUIBB COMPANY | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122005-A1 | Isoxazoline derivatives as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme | MMP2, MMP1, MMP9 | BRD4 2407/4885CYP1A2 346/4885HIF1A 1741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.